Syndax Pharmaceuticals (SNDX) Common Equity (2015 - 2026)

Syndax Pharmaceuticals' Common Equity history runs 12 years deep, the most recent figure standing at $41.6 million for Q1 2026.

• On a quarterly basis, Common Equity fell 80.65% year-over-year to $41.6 million in Q1 2026; TTM through Mar 2026 was $41.6 million, a 80.65% decrease from a year earlier, with the FY2025 full-year figure at $64.6 million, down 77.57% from the prior year.
• Common Equity fell to $41.6 million in Q1 2026 per SNDX's latest filing, from $64.6 million in the prior quarter.
• Across five years, Common Equity topped out at $554.2 million in Q4 2023 and bottomed at $41.6 million in Q1 2026.
• The 5-year median for Common Equity is $361.9 million (2022), against an average of $321.5 million.
• Across the five-year window, Common Equity soared 69.9% in 2022 and slumped 80.65% in 2026, its largest moves.
• Year by year, Common Equity stood at $467.4 million in 2022, then grew by 18.56% to $554.2 million in 2023, then tumbled by 48.01% to $288.1 million in 2024, then plunged by 77.57% to $64.6 million in 2025, then tumbled by 35.6% to $41.6 million in 2026.
• Per Business Quant, the three latest SNDX Common Equity figures stand at $41.6 million (Q1 2026), $64.6 million (Q4 2025), and $115.4 million (Q3 2025).